143 related articles for article (PubMed ID: 16337857)
21. [Comparative genomic hybridization for analysis of chromosomal changes in cisplatin-resistant ovarian cancer].
Kudoh K; Takano M; Koshikawa T; Yoshida S; Hirai M; Kikuchi Y; Nagata I; Miwa M; Uchida K
Hum Cell; 2000 Sep; 13(3):109-16. PubMed ID: 11197772
[TBL] [Abstract][Full Text] [Related]
22. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
[TBL] [Abstract][Full Text] [Related]
23. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Bae JH; Lee JM; Ryu KS; Lee YS; Park YG; Hur SY; Ahn WS; Namkoong SE
Gynecol Oncol; 2007 Jul; 106(1):193-200. PubMed ID: 17466362
[TBL] [Abstract][Full Text] [Related]
24. Advances in treatment of epithelial ovarian cancer.
Kikkawa F; Nawa A; Ino K; Shibata K; Kajiyama H; Nomura S
Nagoya J Med Sci; 2006 Jan; 68(1-2):19-26. PubMed ID: 16579172
[TBL] [Abstract][Full Text] [Related]
25. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
Larsen E; Blaakaer J
Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
[TBL] [Abstract][Full Text] [Related]
26. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer.
Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Puopolo M; Schwartz P; Yu H
Gynecol Oncol; 2006 Dec; 103(3):990-5. PubMed ID: 16859738
[TBL] [Abstract][Full Text] [Related]
27. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
[TBL] [Abstract][Full Text] [Related]
28. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
29. MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.
Pénzváltó Z; Lánczky A; Lénárt J; Meggyesházi N; Krenács T; Szoboszlai N; Denkert C; Pete I; Győrffy B
BMC Cancer; 2014 Nov; 14():837. PubMed ID: 25408231
[TBL] [Abstract][Full Text] [Related]
30. Compliance to clinical guidelines for early-stage epithelial ovarian cancer in relation to patient outcome.
Sijmons EA; van Lankveld MA; Witteveen PO; Peeters PH; Koot VC; van Leeuwen JS
Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):203-8. PubMed ID: 16707204
[TBL] [Abstract][Full Text] [Related]
31. Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma.
van den Broek GB; Wreesmann VB; van den Brekel MW; Rasch CR; Balm AJ; Rao PH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4386-91. PubMed ID: 17671120
[TBL] [Abstract][Full Text] [Related]
32. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
33. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
34. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Bell J; Brady MF; Young RC; Lage J; Walker JL; Look KY; Rose GS; Spirtos NM;
Gynecol Oncol; 2006 Sep; 102(3):432-9. PubMed ID: 16860852
[TBL] [Abstract][Full Text] [Related]
36. High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin-resistant ovarian cancer cells.
Prasad M; Bernardini M; Tsalenko A; Marrano P; Paderova J; Lee CH; Ben-Dor A; Barrett MT; Squire JA
Genes Chromosomes Cancer; 2008 May; 47(5):427-36. PubMed ID: 18273836
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
38. Genetic alterations related to lymph node metastasis and peritoneal dissemination in epithelial ovarian cancers.
Umayahara K; Numa F; Inokuma A; Sueoka K; Kawasaki K; Hirakawa H; Emoto T; Sakaguchi Y; Nawata S; Ogata H; Sakamoto M; Hasumi K; Kawauchi S; Sasaki K; Kato H
Oncol Rep; 2002; 9(5):1115-9. PubMed ID: 12168082
[TBL] [Abstract][Full Text] [Related]
39. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.
Smith G; Ng MT; Shepherd L; Herrington CS; Gourley C; Ferguson MJ; Wolf CR
Br J Cancer; 2012 Oct; 107(8):1327-36. PubMed ID: 22990650
[TBL] [Abstract][Full Text] [Related]
40. [Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer].
Abe A; Ikawa H; Muguruma H; Maeda Y
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1795-8. PubMed ID: 18931592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
